Hemispherx Biopharma said Monday it is deferring all executive bonus payments until the Philadelphia biotechnology company achieves manufacturing goals at it newly renovated plant in North Jersey. According to documents filed with the Securities and Exchange Commission, the employment contracts for both Carter and Equels include the opportunity this year to earn bonuses of up to 25 percent of their base salary.